Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.56 USD | -0.08% | -4.36% | -8.22% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.22% | 1.46B | |
+14.85% | 77.63B | |
+12.05% | 8.78B | |
+57.26% | 4.93B | |
-16.24% | 4.79B | |
+1.45% | 3.8B | |
+22.03% | 2.46B | |
-26.19% | 2.2B | |
+16.04% | 2.1B | |
-37.26% | 1.96B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M